MA45158A - Composition pharmaceutique comprenant de l'éteplirsen - Google Patents

Composition pharmaceutique comprenant de l'éteplirsen

Info

Publication number
MA45158A
MA45158A MA045158A MA45158A MA45158A MA 45158 A MA45158 A MA 45158A MA 045158 A MA045158 A MA 045158A MA 45158 A MA45158 A MA 45158A MA 45158 A MA45158 A MA 45158A
Authority
MA
Morocco
Prior art keywords
éteplirsen
pharmaceutical composition
composition consisting
pharmaceutical
composition
Prior art date
Application number
MA045158A
Other languages
English (en)
Inventor
Thomas Holt
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MA45158A publication Critical patent/MA45158A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA045158A 2016-05-24 2017-05-24 Composition pharmaceutique comprenant de l'éteplirsen MA45158A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662340947P 2016-05-24 2016-05-24
US201662429160P 2016-12-02 2016-12-02

Publications (1)

Publication Number Publication Date
MA45158A true MA45158A (fr) 2019-04-10

Family

ID=59093599

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045158A MA45158A (fr) 2016-05-24 2017-05-24 Composition pharmaceutique comprenant de l'éteplirsen

Country Status (15)

Country Link
US (1) US20190275072A1 (fr)
EP (1) EP3463390A1 (fr)
JP (1) JP2019516730A (fr)
KR (1) KR20190009343A (fr)
CN (1) CN109562123A (fr)
AU (1) AU2017278699A1 (fr)
BR (1) BR112018074299A2 (fr)
CA (1) CA3024178A1 (fr)
CO (1) CO2018013828A2 (fr)
IL (1) IL263040A (fr)
MA (1) MA45158A (fr)
MX (1) MX2018014129A (fr)
SG (1) SG11201809494VA (fr)
TW (1) TW201805002A (fr)
WO (1) WO2017213854A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
EP3806868A4 (fr) * 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. Oligomères induisant un saut d'exon pour la dystrophie musculaire
US20220251551A1 (en) * 2018-06-13 2022-08-11 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
EP3810150A4 (fr) * 2018-06-14 2023-01-25 Sarepta Therapeutics, Inc. Oligomères induisant le saut d'exon et conjugués d'oligomères pour la dystrophie musculaire

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
DE3650699T2 (de) 1985-03-15 1999-04-15 Antivirals Inc Immunotestmittel für Polynukleotid und Verfahren
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
WO1990002749A1 (fr) 1988-09-01 1990-03-22 Forskningscenter Risø Procede de synthese de peptides et support solide de realisation dudit procede
ES2361325T3 (es) 2004-06-28 2011-06-16 The University Of Western Australia Oligonucleótidos antisentido para inducir la omisión de exón y métodos de uso de los mismos.
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
JP5512533B2 (ja) 2007-11-15 2014-06-04 サレプタ セラピューティクス， インコーポレイテッド モルホリノオリゴマーの合成方法
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
JP5831455B2 (ja) 2010-09-30 2015-12-09 日本新薬株式会社 モルホリノ核酸誘導体
AU2012345638C1 (en) 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
CN103933549A (zh) * 2013-01-17 2014-07-23 刘海俊 一种新的血管抑素滴眼剂及其制备方法
EA201591792A1 (ru) * 2013-03-15 2016-02-29 Сарепта Терапьютикс, Инк. Улучшенные композиции для лечения мышечной дистрофии

Also Published As

Publication number Publication date
EP3463390A1 (fr) 2019-04-10
AU2017278699A1 (en) 2018-11-15
US20190275072A1 (en) 2019-09-12
CA3024178A1 (fr) 2017-12-14
WO2017213854A1 (fr) 2017-12-14
SG11201809494VA (en) 2018-12-28
BR112018074299A2 (pt) 2019-03-12
CN109562123A (zh) 2019-04-02
JP2019516730A (ja) 2019-06-20
CO2018013828A2 (es) 2018-12-28
IL263040A (en) 2018-12-31
MX2018014129A (es) 2019-04-29
KR20190009343A (ko) 2019-01-28
TW201805002A (zh) 2018-02-16

Similar Documents

Publication Publication Date Title
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
MA49043A (fr) Formulation stable d'anticorps
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
MA49726A (fr) Formulation d'anticorps anti-cgrp
DK3529248T3 (da) Farmaceutiske sammensætninger
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA46334A (fr) Composition pharmaceutique liquide
DK3479819T3 (da) Stabilt væskeformigt farmaceutisk præparat
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
DK3532029T3 (da) Flydende farmaceutisk sammensætning
DK3634377T3 (da) Farmaceutisk formulering
MA43361A (fr) Composition pour le soin et la protection de cultures
MA43705A (fr) Formulation pharmaceutique
MA47516A (fr) Composition pharmaceutique
MA49116A (fr) Compositions pharmaceutiques contenant de l'insuline
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
MA49837A (fr) Compositions pharmaceutiques
MA42964A (fr) Préparation pharmaceutique anti-vieillissement
DK3672631T3 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer